Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Stock Short Interest Report for October

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 99,181 shares, a drop of 56.7% from the October 15th total of 229,146 shares. Based on an average trading volume of 738,430 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are sold short.

Oncotelic Therapeutics Trading Up 1.5%

Shares of OTLC traded up $0.00 during trading hours on Friday, hitting $0.01. The stock had a trading volume of 479,008 shares, compared to its average volume of 460,984. Oncotelic Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.10. The company’s fifty day simple moving average is $0.02 and its 200 day simple moving average is $0.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08. The firm has a market cap of $6.03 million, a P/E ratio of 0.02 and a beta of -0.10.

Oncotelic Therapeutics Company Profile

(Get Free Report)

Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research includes therapies intended to affect biological pathways involved in tumor growth and the body’s immune response. The company’s lead candidate, OT-101, is an antisense therapy designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has pursued its development for cancers including glioblastoma and pancreatic cancer; it remains an investigational drug, not an approved treatment.

Further Reading

Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.